조산 및 양막 조기 파열(PROM) 검사 시장 - 세계 예측(2026-2032년)

The Preterm Birth & PROM Testing Market is projected to grow by USD 2.14 billion at a CAGR of 5.62% by 2032.

Preterm birth and premature rupture of membranes (PROM) testing sit at the center of maternal-fetal risk management, neonatal morbidity reduction, and evidence-based obstetric triage. Preterm birth, defined by the World Health Organization as birth before 37 completed weeks of gestation, remains a leading cause of death among children under five, while PROM and preterm PROM (PPROM) increase the risk of intra-amniotic infection, placental complications, cord compression, and early delivery. As health systems prioritize timely diagnosis, PROM testing is increasingly used alongside clinical assessment, ultrasound, fetal monitoring, cervical evaluation, and laboratory markers to distinguish true membrane rupture from physiologic discharge, urinary leakage, or bleeding-related diagnostic uncertainty. The clinical value of preterm birth and PROM testing is strongest when it supports faster decision-making on hospitalization, antenatal corticosteroid administration, magnesium sulfate for fetal neuroprotection when indicated, antibiotics when clinically appropriate, transfer to higher-level neonatal care, and delivery timing. Demand is shaped by rising awareness of high-risk pregnancy management, expanding antenatal care coverage, increasing use of point-of-care diagnostics, and the need to reduce unnecessary admissions and interventions. The landscape is also influenced by variations in regulatory pathways, reimbursement policies, infection prevention protocols, and access to skilled obstetric and neonatal services. For healthcare leaders, the strategic priority is not simply test adoption but the integration of accurate, rapid, and workflow-compatible diagnostic pathways that improve maternal and neonatal outcomes while supporting antimicrobial stewardship and resource-efficient obstetric care.

Transformative Shifts in the Preterm Birth and PROM Testing Landscape

The preterm birth and PROM testing landscape is being reshaped by a shift from symptom-based evaluation toward objective, protocol-driven diagnostics that can be performed rapidly in triage, emergency obstetric units, and outpatient settings. Traditional assessment methods such as sterile speculum examination, pooling, nitrazine testing, and ferning remain clinically relevant, but their performance can be affected by semen, blood, infection, lubricants, and examiner variability. This has accelerated the use of biomarker-based tests that detect proteins associated with amniotic fluid, as well as combined approaches that align diagnostic results with gestational age, maternal infection status, fetal wellbeing, and cervical findings. Another major transformation is the growing focus on risk stratification rather than single-test decision-making. Health systems are increasingly linking PROM testing with preterm labor assessment, cervical length measurement, fetal fibronectin or other biochemical markers where appropriate, and standardized care bundles for threatened preterm birth. Digital documentation, electronic triage pathways, and quality improvement programs are also reducing variation in care, particularly in facilities with high delivery volumes. At the same time, maternal health equity has become a defining theme. Countries with limited access to prenatal care, laboratory infrastructure, and neonatal intensive care face a higher burden of preventable adverse outcomes, making affordable, easy-to-use, and reliable PROM testing especially important. The most significant shift is therefore operational: diagnostics are moving from isolated clinical tools to embedded components of maternal-fetal safety systems.

Cumulative Impact of Artificial Intelligence on Preterm Birth and PROM Testing

Artificial intelligence is beginning to influence preterm birth and PROM testing through risk prediction, workflow optimization, and clinical decision support rather than through standalone diagnosis. Data-backed clinical practice increasingly recognizes that preterm birth is multifactorial, involving prior obstetric history, cervical length, infection, inflammation, maternal comorbidities, multiple gestation, socioeconomic factors, and environmental exposures. AI-enabled models can help analyze structured and unstructured electronic health records to identify patients who may require closer surveillance, earlier referral, or targeted intervention; however, clinical validation, bias assessment, and local calibration remain essential before broad deployment. In PROM-related care, AI can support triage by integrating symptom presentation, test results, gestational age, ultrasound findings, vital signs, laboratory markers, and fetal status into standardized risk pathways. It can also improve operational efficiency by predicting demand for obstetric observation beds, neonatal intensive care capacity, corticosteroid use, and transfer requirements. The cumulative impact is likely to be strongest where AI is implemented as an assistive layer within evidence-based protocols, not as a replacement for clinician judgment. Key safeguards include transparent model performance reporting, representative training datasets, privacy-preserving data governance, continuous monitoring for demographic bias, and clear accountability for clinical decisions. In mature settings, AI may enhance predictive accuracy and reduce avoidable admissions; in resource-constrained settings, carefully designed digital tools may extend specialist expertise to frontline maternal care when supported by training and connectivity.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific carries a substantial maternal and neonatal health burden due to large birth cohorts, heterogeneous prenatal care access, and wide differences in tertiary obstetric capacity between urban and rural areas. Countries across the region are strengthening antenatal screening, referral systems, and facility-based birth preparedness, creating a practical need for rapid PROM testing that can guide timely transfer and intervention. North America is characterized by advanced obstetric triage infrastructure, high use of point-of-care diagnostics, established neonatal intensive care networks, and strong emphasis on guideline-driven management of PPROM and threatened preterm labor. In this region, adoption is shaped by diagnostic accuracy, integration with electronic health records, reimbursement alignment, and efforts to reduce racial, geographic, and socioeconomic disparities in preterm birth outcomes. Latin America faces persistent variability in prenatal care quality and access to specialist obstetric services, making PROM testing relevant for improving triage consistency, particularly in public health systems serving geographically dispersed populations. Europe benefits from structured maternal care pathways, high rates of skilled birth attendance, and strong regulatory scrutiny for in vitro diagnostics, with increasing attention to standardized protocols, antimicrobial stewardship, and cross-border evidence harmonization. The Middle East shows rising demand for maternal-fetal medicine capabilities, driven by investment in hospital infrastructure, high-risk pregnancy services, and national health modernization programs, while PROM testing is increasingly positioned within broader obstetric emergency preparedness. Africa continues to face the highest access challenges, including shortages of skilled providers, diagnostic infrastructure, and neonatal intensive care capacity in many areas; therefore, affordable and robust PROM testing has particular public health value when linked to infection prevention, referral pathways, and basic emergency obstetric and newborn care.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are prioritizing maternal and newborn health through expanded antenatal care coverage, hospital delivery access, and public health programs that address preventable neonatal complications, making PROM testing important for timely triage across mixed public-private healthcare systems. The GCC has invested heavily in advanced hospital infrastructure, specialized women's health services, and digital health transformation, supporting the integration of rapid obstetric diagnostics into high-acuity care pathways for high-risk pregnancies. The European Union provides a highly regulated environment for diagnostic quality, clinical evidence, data protection, and patient safety, which encourages standardized PROM testing protocols and careful evaluation of test performance across diverse healthcare systems. BRICS countries represent a broad range of maternal health realities, from highly advanced urban tertiary centers to underserved rural networks; their common need is scalable, cost-conscious diagnostic access that can reduce delays in identifying membrane rupture and managing preterm birth risk. G7 countries typically have mature neonatal care systems, established obstetric guidelines, and sophisticated reimbursement and procurement processes, so decisions around PROM testing often focus on clinical utility, workflow efficiency, false-positive reduction, and health equity improvement. NATO member countries overlap with several high-income and upper-middle-income health systems that emphasize readiness, supply chain resilience, digital interoperability, and evidence-based care; within these systems, PROM testing is increasingly viewed as part of resilient maternal healthcare infrastructure that must remain reliable during public health emergencies, migration pressures, and workforce constraints.

Key Country Insights Across Major Preterm Birth and PROM Testing Markets

The United States has a significant preterm birth burden compared with many other high-income countries, with documented disparities by race, income, geography, and access to prenatal care, making accurate PROM testing central to obstetric triage and unnecessary intervention reduction. Canada emphasizes universal healthcare access, regionalized perinatal care, and evidence-based maternal-fetal referral systems, supporting the use of PROM diagnostics in coordinated care pathways across large geographies. Mexico and Brazil face mixed public-private maternal care environments and regional disparities, where rapid and affordable PROM testing can support earlier risk identification and more consistent referral decisions. The United Kingdom relies on national clinical guidance, structured maternity pathways, and quality improvement programs, creating strong alignment between PROM testing and standardized management of suspected membrane rupture. Germany, France, Italy, and Spain have well-developed obstetric and neonatal systems, where diagnostic adoption is influenced by evidence quality, reimbursement, infection control standards, and hospital procurement practices. Russia's large geography and uneven access to specialist perinatal services make scalable diagnostics relevant for strengthening regional maternity care. China and India, with large birth populations and major policy focus on maternal and newborn outcomes, show strong need for reliable testing that can function across both advanced urban hospitals and resource-variable settings. Japan, Australia, and South Korea combine advanced perinatal care systems with aging maternal demographics and high expectations for diagnostic precision, making PROM testing valuable within high-risk pregnancy management, preterm labor assessment, and neonatal preparedness strategies.

Actionable Recommendations for Leaders in Preterm Birth and PROM Testing

Industry leaders should prioritize clinically validated PROM testing solutions that demonstrate reliability across real-world conditions, including blood contamination, infection, variable gestational ages, and diverse patient populations. Product development should focus on rapid turnaround time, ease of use, minimal training requirements, clear result interpretation, and compatibility with obstetric triage workflows. To support adoption, healthcare stakeholders should invest in implementation evidence that links testing to meaningful outcomes such as reduced diagnostic uncertainty, optimized admissions, appropriate use of corticosteroids and antibiotics, timely referral, and reduced unnecessary interventions. Regulatory and quality strategies should be designed early, with robust analytical validation, clinical performance data, post-market surveillance, and compliance with evolving in vitro diagnostic regulations. For health systems, the priority is to embed PROM testing into standardized preterm labor and PPROM pathways rather than using tests in isolation. Training programs should reinforce correct sample collection, interpretation, documentation, and escalation steps. Partnerships with public health agencies, maternity networks, and professional societies can improve protocol adherence and equitable access. In lower-resource settings, leaders should emphasize affordability, supply stability, temperature tolerance, and decentralized usability. Across all settings, data integration with electronic medical records and AI-ready clinical datasets can create long-term value, provided privacy, consent, and bias controls are maintained.

Research Methodology for Preterm Birth and PROM Testing Analysis

This executive summary is structured around evidence-based secondary research and clinical knowledge synthesis from authoritative public health, regulatory, and medical sources. The research approach emphasizes verified information from international health agencies, national public health bodies, peer-reviewed obstetrics and gynecology literature, clinical practice guidelines, diagnostic regulatory frameworks, and maternal-newborn health policy resources. The methodology excludes market sizing, revenue estimation, market share calculation, and forecasting. Evidence was assessed for relevance to preterm birth, PROM, PPROM, diagnostic testing performance, obstetric triage, maternal-fetal outcomes, regional health system readiness, and adoption barriers. Regional, group, and country insights were developed by comparing healthcare infrastructure maturity, prenatal care access, neonatal service capacity, regulatory rigor, public health priorities, and documented maternal health disparities. The analysis also considered the operational role of diagnostics in emergency obstetric care, referral decisions, antimicrobial stewardship, and neonatal preparedness. AI-related insights were evaluated through the lens of clinical decision support, predictive analytics, data governance, and implementation safety, with emphasis on validation and bias mitigation. This methodology supports an optimized yet clinically grounded perspective for stakeholders seeking to understand the evolving role of preterm birth and PROM testing without relying on speculative commercial projections.

Conclusion: Advancing Maternal-Fetal Outcomes Through Better PROM Testing

Preterm birth and PROM testing are becoming increasingly important components of modern maternal-fetal care because they help clinicians make timely, evidence-based decisions in scenarios where diagnostic uncertainty can affect both maternal and neonatal outcomes. The strongest opportunities lie in integrating accurate PROM diagnostics into standardized triage protocols, high-risk pregnancy pathways, referral networks, and digital health systems. Regional needs differ substantially: high-income health systems are focused on precision, workflow efficiency, equity, and regulatory compliance, while resource-constrained settings require affordable, robust, and decentralized testing that supports safe referral and infection prevention. Artificial intelligence may strengthen preterm birth risk prediction and operational planning, but its value depends on validated models, representative datasets, and responsible clinical governance. For industry leaders, success will depend on clinical credibility, usability, regulatory readiness, and the ability to demonstrate practical value within real obstetric workflows. As maternal health systems continue to prioritize preventable neonatal morbidity and mortality, PROM testing will remain a critical diagnostic tool within broader strategies to improve pregnancy outcomes, optimize care delivery, and support safer births worldwide.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Preterm Birth & PROM Testing Market, by Test Category

• 7.1. Introduction
• 7.2. Preterm Birth Testing
• 7.3. Premature Rupture of Membranes Testing

8. Preterm Birth & PROM Testing Market, by Technology

• 8.1. Introduction
• 8.2. Immunoassay
• 8.3. Molecular Diagnostics
• 8.4. Imaging Technologies
• 8.5. Sensor-Based Monitoring

9. Preterm Birth & PROM Testing Market, by Testing Mode

• 9.1. Introduction
• 9.2. Point-of-Care (POC) Testing
• 9.3. Laboratory-Based Testing
• 9.4. Continuous Monitoring Systems

10. Preterm Birth & PROM Testing Market, by Product Type

• 10.1. Introduction
• 10.2. Diagnostic Kits
• 10.3. Instruments & Analyzers
• 10.4. Consumables
• 10.5. Software & Algorithms

11. Preterm Birth & PROM Testing Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Care
• 11.3. Diagnostic Laboratories
• 11.4. Hospitals & Clinics
• 11.5. Research Institutes

12. Preterm Birth & PROM Testing Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Preterm Birth & PROM Testing Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Preterm Birth & PROM Testing Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Arkray, Inc.
• 16.3. Beckman Coulter, Inc.
• 16.4. Becton, Dickinson and Company
• 16.5. Bio-Rad Laboratories, Inc.
• 16.6. Biosynex S.A.
• 16.7. CooperSurgical, Inc.
• 16.8. Danaher Corporation
• 16.9. F. Hoffmann-La Roche Ltd
• 16.10. Ferring Pharmaceuticals A/S
• 16.11. Hologic Gen-Probe Incorporated
• 16.12. Laborie Medical Technologies Corp.
• 16.13. Medix Biochemica Oy
• 16.14. Metabolomic Diagnostics Ltd
• 16.15. NX Prenatal Diagnostics Ltd
• 16.16. Ortho Clinical Diagnostics Holdings plc
• 16.17. Panache HealthNeeds Pvt Ltd
• 16.18. PerkinElmer, Inc.
• 16.19. Progyny, Inc.
• 16.20. QIAGEN N.V.
• 16.21. Sera Prognostics Europe B.V.
• 16.22. Siemens Healthineers AG
• 16.23. Sysmex Corporation
• 16.24. Thermo Fisher Scientific Inc.
• 16.25. Toda Pharma